Patient characteristics
| Patient . | Sex (M/F) . | Age at diagnosis, years . | t(11;14) . | White blood cells ×109/L . | L . | H . | S . | Therapy* . | Survival, months† . |
|---|---|---|---|---|---|---|---|---|---|
| B-PLL 1 | M | 61 | No | 39 | No | No | Yes | Chemo | 135+ |
| B-PLL 2 | F | 59 | No | 30 | No | No | Yes | Chemo | 5 |
| B-PLL 3 | M | 70 | No | 173 | No | No | Yes | Chemo | 39 |
| B-PLL 4 | F | 84 | No | 180 | No | No | Yes | Chemo | 14 |
| B-PLL 5 | M | 49 | No | 53 | Yes | Yes | Yes | Chemo, SCT | 199+ |
| B-PLL 6 | M | 43 | No | 210 | Yes | No | Yes | Chemo | 97 |
| B-PLL 7 | M | 69 | Yes | 30 | No | No | Yes | Splen | 2.5 |
| B-PLL 8 | F | 74 | Yes | 6 | Yes | No | Yes | Splen, chemo | 108 |
| B-PLL 9 | M | 60 | Yes | 227 | No | No | Yes | Splen, chemo | 82+‡ |
| B-PLL 10 | M | 43 | Yes | 192 | Yes | No | Yes | Splen, chemo | 6 |
| B-PLL 11 | F | 63 | Yes | 37 | No | No | Yes | Splen, chemo | 19 |
| B-PLL 12 | M | 52 | Yes | 241 | Yes | Yes | Yes | Chemo | 12 |
| B-PLL 13 | F | 44 | Yes | 116 | No | Yes | Yes | Splen, chemo | 24 |
| Patient . | Sex (M/F) . | Age at diagnosis, years . | t(11;14) . | White blood cells ×109/L . | L . | H . | S . | Therapy* . | Survival, months† . |
|---|---|---|---|---|---|---|---|---|---|
| B-PLL 1 | M | 61 | No | 39 | No | No | Yes | Chemo | 135+ |
| B-PLL 2 | F | 59 | No | 30 | No | No | Yes | Chemo | 5 |
| B-PLL 3 | M | 70 | No | 173 | No | No | Yes | Chemo | 39 |
| B-PLL 4 | F | 84 | No | 180 | No | No | Yes | Chemo | 14 |
| B-PLL 5 | M | 49 | No | 53 | Yes | Yes | Yes | Chemo, SCT | 199+ |
| B-PLL 6 | M | 43 | No | 210 | Yes | No | Yes | Chemo | 97 |
| B-PLL 7 | M | 69 | Yes | 30 | No | No | Yes | Splen | 2.5 |
| B-PLL 8 | F | 74 | Yes | 6 | Yes | No | Yes | Splen, chemo | 108 |
| B-PLL 9 | M | 60 | Yes | 227 | No | No | Yes | Splen, chemo | 82+‡ |
| B-PLL 10 | M | 43 | Yes | 192 | Yes | No | Yes | Splen, chemo | 6 |
| B-PLL 11 | F | 63 | Yes | 37 | No | No | Yes | Splen, chemo | 19 |
| B-PLL 12 | M | 52 | Yes | 241 | Yes | Yes | Yes | Chemo | 12 |
| B-PLL 13 | F | 44 | Yes | 116 | No | Yes | Yes | Splen, chemo | 24 |
Chemo, chemotherapy (fludarabine [8 patients]; fludarabine, cyclophosphamide, rituximab [2 patients]; alemtuzumab [1 patient]; CHOP: cyclophosphamide, doxorubicin, vincristine, prednisone [6 patients]; DHAP: dexamethasone, cytarabine, cisplatin [3 patients]; chlorambucil [3 patients]; deoxycoformycin [1 patient]; high-dose cytarabine [1 patient]); H, hepatomegaly; L, lymphadenopathy;); S, splenomegaly; Splen, splenectomy; SCT, allogeneic sibling stem cell transplantation.
Splenectomy was particularly performed in patients diagnosed before 2001, when chemotherapeutic options to reduce spleen size were still limited. Spleen size was comparable between patients diagnosed before or after 2001. Morphological data from the removed spleen were available from patients 7, 8, 10, 11, and 13. B-PLL10 showed disrupted architecture with infiltration of prolymphocyte-like cells in particularly the red pulpa. B-PLL7 and B-PLL8 showed disrupted architecture with infiltration of MCL-like cells (either classical or monocytoid). B-PLL11 showed normal splenic architecture without clear leukemic infiltration. B-PLL13 showed normal splenic architecture with focal infiltration of atypical lymphocytes (some with a clear nucleolus), also in the red pulpa.
+, Still alive at last follow-up (2013).
Subsequently lost to follow-up.